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Alzheimer’s disease (AD) is the most common form of dementia clinically characterized by progressive impairment of memory
and other cognitive functions. Many genetic researches in AD identified one common genetic variant (ε4) in Apolipoprotein E
(APOE) gene as a risk factor for the disease. Two independent genome-wide studies demonstrated a new locus on chromosome
9p21.3 implicated in Late-Onset Alzheimer’s Disease (LOAD) susceptibility in Caucasians. In the present study, we investigated the
role of three SNP’s in the CDKN2A gene (rs15515, rs3731246, and rs3731211) and one in the CDKN2B gene (rs598664) located
in 9p21.3 using an association case-control study carried out in a group of Caucasian subjects including 238 LOAD cases and 250
controls. The role of CDKN2A and CDKN2B genetic variants in AD is not confirmed in our LOAD patients, and further studies
are needed to elucidate the role of these genes in the susceptibility of AD.
1. Introduction
Alzheimer’s disease (AD) is the most common form of
dementia clinically characterized by insidious onset and
progressive impairment of memory and other cognitive
functions [1], ultimately resulting in complete dependency
and death of the patient.
The key features of AD brains are neuronal and synapse
loss, extracellular plaques composed of amyloid-β (Aβ)
peptides and intraneuronal neurofibrillary tangles consisting
of hyperphosphorylated tau protein.
Although most patients develop AD at later age, with
a prevalence estimates ranging from 4.4% in persons aged
65 years to 22% at ages 90 and older [2], it is mainly the
research performed on the rare autosomal dominant early-
onset form of AD that provided valuable insights into disease
pathogenesis.
Several penetrant autosomal dominant mutations have
been identified (http://www.molgen.ua.ac.be/ADMutations/),
leading to early-onset familial AD within three genes: pre-
senilin 1 (PSEN1) [3], presenilin 2 (PSEN2) [4], and amyloid
precursor protein (APP) genes [5].
The Apolipoprotein E gene (APOE) was identified as a
major risk factor contributing to the pathogenesis of late-
onset Alzheimer disease’s (LOAD) [6]. However, the APOE
e4 allele is neither necessary nor sufficient for the occurrence
of the disease.
Many SNPs have been analyzed to identify new suscepti-
bility candidate genes for the LOAD [7].
Recently, two independent genome-wide studies have
demonstrated a new locus on chromosome 9p21.3 impli-
cated in LOAD susceptibility in Caucasians [8, 9].
Zu¨chner and colleagues in their work individuated
several SNPs in three different genes: the cyclin-dependent
kinase inhibitors (CDKN2A, CDKN2B) and methylth-
ioadenosine phosphorylase (MTAP), and they conducted an
allelic association test to evaluate the genetic effect of these
genes [9].
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In light of these results, we investigated the role of
three SNP’s in the CDKN2A gene (rs11515, rs3731246, and
rs3731211) and one in the CDKN2B gene (rs598664) using
an association study carried out in a group of Caucasian
LOAD patients.
2. Materials andMethods
2.1. Patients. Our study group included 488 Caucasian
subjects: 238 LOAD patients (63.9% females, age at onset
72.9± 5.6 years, mean± SD, Mini Mental State Examination
score 20.2 ± 5.4 points) and 250 nondemented controls
(62.4% females, mean age 71.5 ± 5.7 years; SD) (Table 1).
All subjects were enrolled in the study at the Neurology
Unit of the Department of Neurological and Psychiatric
Sciences of the University of Florence and at Paul Flechsig
Institute for Brain Research, University of Leipzig, Germany.
Patients (19.7% autopsy proven) were clinically evaluated
according to published guidelines, and the AD diagnosis
fulfilled the Diagnostic and Statistical Manual of Mental
Disorders criteria (DSM-IV) [10, 11]. Presence of a family
history of dementia was considered an exclusion criterion.
All controls were carefully assessed using a rigorous
clinical history evaluation and a general/neurological exam-
ination, in order to exclude the presence of any neurological
disorder.
The study protocol was approved by the local ethics
committee and conducted in accordance with the provisions
of the Helsinki Declaration; informed consent for genetic
screening was obtained from the study participants or, where
appropriate, a relative or legal representative.
2.2. Genotyping. DNA was extracted from white blood
cells using the phenol-chloroform procedure and all of
the genotyping was performed by KBioscience (http://www
.kbioscience.co.uk/). KBiosciences uses a novel form of
competitive allele specific PCR system (KASPar) that is a
proprietary KBioscience invented genotyping chemistry. The
accuracy greater than 99% is achieved and a routine quality
control measures is performed on all genotyping.
APOE genotypes were determined in all subjects using
polymerase chain reaction (PCR) and restriction frag-
ment length polymorphism (RFLP) methods, as previously
described [12].
2.3. Statistics. Differences in distribution between cases and
controls were tested using chi-square test (EpiInfo software
v. 3.3.2 available free at http://www.cdc.gov/EpiInfo/).
In order to evaluate the association between genotypes
and alleles and AD, odds ratios (ORs) and corresponding
95% confidence intervals (CIs) were calculated using logistic
regression models (SPSS software ver. 18.0 for Windows
(Chicago, ILL, USA)). Further analysis were performed by
using logistic regression models adjusted for gender, age (in
continuous), and presence of APOE e4.
A P-value of <.05 was considered statistically significant.
A power analysis was performed using COMPARE2
software (available free at http://www.brixtonhealth.com/).
Table 1: Main characteristics of all studied subjects.
Characteristics LOADa Controls
Total 238 250
Gender, no. (%)
Female 152 (63.9) 156 (62.4)
Male 86 (36.1) 94 (38.6)
Recruitment site, no. (%)
Italy 218 (91.6) 230 (92)
Germany 20 (8.4) 20 (8)
Age at onsetb, mean (±SD) 72.9 (±5.6) 71.5 (±5.7)
MMSE points, mean (±SD) 20.2 (±5.4) 28.2 (±1.4)
APOE ε4, no. (%)
No 133 (55.9) 221 (88.4)
Yes 105 (44.1) 29 (11.6)
a
LOAD cases were defined by the occurrence of Alzheimer’s disease with an
onset age ≥65 years.
bAt examination tests for controls.
Linkage disequilibrium (LD) between the SNPs was
analyzed using PowerMarker software, version 3.25) (http://
statgen.ncsu.edu/powermarker/) [13].
3. Results
Table 1 gives the distribution of 238 LOAD cases and 250
controls according to gender, recruitment site, age, and other
selected characteristics.
Cases and controls had similar recruitment site and
age distribution. The mean of the Mini Mental State
Examination score (MMSE) points was higher in controls
than cases. Conversely, cases reported more frequently the
presence of E4 compared to controls (44.1% versus 11.6%).
The frequencies of all SNPs were in Hardy-Weinberg
equilibrium in AD patients and controls.
Moreover, no correlation between mean age at onset and
all SNPs genotypes was observed and no interaction between
APOE gene was found (data not shown).
We found no differences in the allelic or genotypic
frequencies between AD patients and controls for any of the
SNPs (Table 2). We found no association between AD and
rs11515 genotype (χ2 = 3.47; P = .17) and allele (χ2 = 3.2;
P = .07), rs3731246 genotype (χ2 = 1.13; P = .56) and allele
(χ2 = 1.17; P = .27), rs3731211 genotype (χ2 = 0.57; P =
.75) and allele (χ2 = 0.0; P = .96), rs598664 genotype
(χ2 = 1.11; P = .57), and allele (χ2 = 1.15; P = .28). None of
the unadjusted ORs were statistically significant, and when
we adjusted for gender, age (in continuous), and APOE e4
these results did not substantially change (data not shown).
Moreover, as reported by Zu¨chner and colleagues, we
found that rs11515 SNP was in Linkage Disequilibrium (LD)
with rs37361246 (r2 = 0.64), rs3731211 (r2 = 0.33) and
rs598664 (r2 = 0.55).
4. Discussion
Recent studies reported informative results regarding geno-
mewide association and linkage studies on chromosome 9
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Table 2: CDKN2A/B polymorphisms: genotype, allele frequencies, and unadjusted odds ratios (OR) and corresponding 95% confidence
intervals (CI) for 238 Late-Onset Alzheimer’s Disease (LOAD) cases and 250 controls.
LOADa no. (%) Controls no. (%) χ2 (df, P-value) unadjusted OR (95% CI)
Total 238 250
CDKN2A
Rs 11515
Genotypes 3.47 (2, .17)
CC 169 (71) 163 (65.2) 1b
CG 62 (26) 72 (28.8) 0.83 (0.54–1.27)
GG 7 (3) 15 (6) 0.45 (0.16–1.21)
Alleles 3.20 (1, .07)
C 400 (84) 398 (79) 1b
G 76 (16) 102 (21) 0.74 (0.53–1.04)
Rs 3731246
Genotypes 1.13 (2, .56)
GG 183 (76.9) 182 (72.8) 1b
GC 50 (21) 61 (24.4) 0.82 (0.52–1.28)
CC 5 (2.1) 7 (2.8) 0.71 (0.19–2.55)
Alleles 1.17 (1, .27)
G 416 (87.4) 425 (85) 1b
C 60 (12.6) 75 (15) 0.82 (0.56–1.2)
Rs 3731211
Genotypes 0.57 (2, .75)
TT 105 (44.1) 106 (42.4) 1b
AT 99 (41.6) 112 (44.8) 0.89 (0.60–1.33)
AA 34 (14.3) 32 (12.8) 1.07 (0.59–1.93)
Alleles 0.00 (1, .96)
T 309 (64.9) 324 (64.8) 1b
A 167 (35.1) 176 (35.2) 0.99 (0.76–1.31)
CDKN2B
Rs 598664
Genotypes 1.11 (2, .57)
AA 182 (74.5) 181 (72.4) 1b
AG 51 (21.4) 62 (24.8) 0.82 (0.52–1.28)
GG 5 (2.1) 7 (2.8) 0.71 (0.19–2.55)
Alleles 1.15 (1, .28)
A 415 (87.2) 424 (84.8) 1b
G 61 (12.8) 76 (15.2) 1.35 (0.89–2.07)
a
LOAD cases were defined by the occurrence of Alzheimer’s disease with an onset age ≥65 years.
bReference category.
as candidate region for LOAD. In particular, Pericak-Vance
and colleagues identified the LOAD locus on 9p21.3 in a
genomewide microsatellite-based linkage screen on 466 AD
families [14] and confirmed in a genetic study of a consan-
guineous Israeli-Arab community [15]. In 2007 Hamshere
and colleagues analyzing 723 affected relative pairs with
genomewide linkage analysis showed evidence for disease
locus for LOAD on chromosome 9p [8]. In 2008 Zu¨chner
identified a chromosomal area under the linkage peak con-
taining several potential AD candidate genes and analyzed
CDKN2A and CDKN2B genes. Among the different SNPs
identified, the rs11515 localized in the 3′-UTR of CDKN2A
was the most significant even if no transcription-factor-
binding site, micro-RNA target site, or conserved regulatory
potential has been detected; other SNPs are all in intron
regions.
Many studies have been carried out on numerous pu-
tative gene polymorphisms candidate in AD pathogenesis
and, with the exception of APOE, that is, the only confirmed
genetic risk factor, results are still contrasting.
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In our case-control association study we analyzed four
SNPs, three in the CDKN2A gene (rs15515, rs3731246, and
rs3731211) and one in CDKN2B (rs598664) in a sample
of 488 Caucasian subjects including 238 LOAD and 250
controls.
Our data set of 238 LOAD patients was evaluated as
having a power to detect an OR of 2.0 at a 5% significance
rate between 86.7 and 96.6 for all SNPs. However, to detect
an OR at 1.5—the usual genetic main-effect for complex
disorder—our data has a power between 40.4 and 59 for
all SNPs. Thus, the study is not sufficiently powered and
this is one of the limitations of our study. We did not
find any association between these SNPs and AD risk in
contrast to Zu¨chner’s results: this may be due to the different
study design. In fact, Zu¨chner and colleagues reported a
linkage and association study in 674 AD families, whilst we
conducted a case control association study. Moreover, only
in 47 patients (19.7%) of AD cases the autopsy confirmed
the diagnosis.
Furthermore no correlation between mean age at onset
and all SNPs genotypes, and no interaction between APOE
gene was observed, suggesting that the genes do not act
synergistically.
5. Conclusion
In conclusion, our results did not confirm the hypothesis,
suggested by Zu¨chner and colleagues that CDKN2A and
CDKN2B at 9p21 are implicated in the susceptibility in the
LOAD.
In fact, our data show no evidence of an association
between all the studied SNPs and disease risks, thus a possible
role of CDKN2A and CDKN2B as a genetic risk factor
implicated in the susceptibility to AD was not confirmed. In
lights of these contrasting results further studies are needed
to elucidate the role of these genes in the susceptibility
of AD.
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